7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Marfan Syndrome Decreases Ca 2+ Wave Frequency and Vasoconstriction in Murine Mesenteric Resistance Arteries without Changing Underlying Mechanisms

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background/Aims: Vascular smooth muscle in Marfan syndrome, a connective tissue disorder caused by mutations in FBN1 encoding fibrillin-1, is associated with decreased tonic contraction. As Ca<sup>2+</sup> waves are tightly associated with vasoconstriction, we hypothesized decreased tonic contraction in Marfan syndrome is due to aberrant Ca<sup>2+</sup> wave signaling. Methods: Isometric force and intracellular Ca<sup>2+</sup> were measured from second-order mesenteric arteries from mice heterozygous for the Fbn1 allele encoding a cysteine substitution ( Fbn1<sup>C1039G/+</sup>). Results: Phenylephrine concentration-dependently induced tonic contraction associated with sustained repetitive oscillations in intracellular [Ca<sup>2+</sup>] in both control and Marfan vessels, although Marfan vessels displayed significantly decreased Ca<sup>2+</sup> wave frequency and decreased number of cells exhibiting waves. Inhibition of sarcoplasmic reticulum Ca<sup>2+</sup> re-uptake by cyclopiazonic acid abolished Ca<sup>2+</sup> waves, dramatically decreasing tonic contraction. Nifedipine significantly reduced Ca<sup>2+</sup> wave frequency and tonic contraction, while the nifedipine-insensitive component was abolished by SKF-96365. Ca<sup>2+</sup> waves and tonic contraction were abolished by 2-aminoethoxydiphenylborate, but were unaffected by ryanodine or tetracaine. Conclusion: Phenylephrine-induced Ca<sup>2+</sup> waves underlie tonic contraction in resistance-sized mesenteric arteries and appear to be produced by repetitive cycles of regenerative Ca<sup>2+</sup> release from the sarcoplasmic reticulum. Decreased frequency of Ca<sup>2+</sup> waves in Marfan syndrome appears to be responsible for reduced tonic contraction.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          2-aminoethoxydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2+ entry but an inconsistent inhibitor of InsP3-induced Ca2+ release.

          Since its introduction to Ca2+ signaling in 1997, 2-aminoethoxydiphenyl borate (2-APB) has been used in many studies to probe for the involvement of inositol 1,4,5-trisphosphate receptors in the generation of Ca2+ signals. Due to reports of some nonspecific actions of 2-APB, and the fact that its principal antagonistic effect is on Ca2+ entry rather than Ca2+ release, this compound may not have the utility first suggested. However, 2-APB has thrown up some interesting results, particularly with respect to store-operated Ca2+ entry in nonexcitable cells. These data indicate that although it must be used with caution, 2-APB can be useful in probing certain aspects of Ca2+ signaling.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome.

            Thoracic aortic aneurysm (TAA) is the life-threatening complication of Marfan syndrome (MFS), a connective tissue disorder caused by mutations in the fibrillin-1 gene. TAA is characterized by degradation of elastic fiber, suggesting the involvement of matrix metalloproteinase (MMP)-2 and -9, the activation of which is regulated by TIMP (tissue inhibitor of MMP) types 1 and 2. We hypothesized that MMP-2 and -9 were upregulated during TAA formation in Marfan syndrome, causing loss of elastic fibers and structural integrity. We studied mice, from 3 to 12 months, heterozygous for a mutant Fbn1 allele encoding a cysteine substitution in fibrillin-1 (Fbn1(C1039G/+), designated as "Marfan" mice) (n=120), the most common class of mutation in Marfan syndrome. The littermates, Fbn1(+/+) served as controls (n=120). In Marfan aneurysmal thoracic aorta, mRNA and protein expression of MMP-2 and -9 were detected at 3 months and peaked at 6 months of age, accompanied by severe elastic fiber fragmentation and degradation. From 3 to 9 months, the MMP-2/TIMP-2 ratio increased by 43% to 63% compared with the controls. Dilated thoracic aorta demonstrated increased elasticity but distention caused a pronounced loss of contraction, suggesting weakening of the aortic wall. Breaking stress of the aneurysmal aorta was 70% of the controls. Contraction in response to depolarization and receptor stimulation decreased in the aneurysmal thoracic aorta by 50% to 80%, but the expression of alpha-smooth muscle actin between the 2 strains was not significantly different. This report demonstrates the upregulation of MMP-2 and -9 during TAA formation in Marfan syndrome. The resulting elastic fiber degeneration with deterioration of the aortic contraction and mechanical properties may explain the pathogenesis of TAA.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome

                Bookmark

                Author and article information

                Journal
                JVR
                J Vasc Res
                10.1159/issn.1018-1172
                Journal of Vascular Research
                S. Karger AG
                1018-1172
                1423-0135
                2011
                February 2011
                08 October 2010
                : 48
                : 2
                : 150-162
                Affiliations
                aDepartment of Anesthesiology, Pharmacology and Therapeutics, and bCardiovascular Sciences, Child and Family Research Institute, University of British Columbia, Vancouver, B.C., Canada
                Author notes
                *Dr. Cornelis van Breemen, Cardiovascular Sciences, Child and Family Research Institute, Room 2099, 950 W 28th Ave, Vancouver, BC V5Z 4H4 (Canada), Tel. +1 604 875 3852, Fax +1 604 875 3120, E-Mail breemen@interchange.ubc.ca
                Article
                318804 J Vasc Res 2011;48:150–162
                10.1159/000318804
                20926894
                9c275e3f-d214-4c77-bce7-9b8476754371
                © 2010 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 04 February 2010
                : 10 June 2010
                Page count
                Figures: 9, References: 62, Pages: 13
                Categories
                Research Paper

                General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
                Calcium waves,Mesenteric artery,Vascular smooth muscle,Isometric force,Marfan syndrome,Confocal microscopy

                Comments

                Comment on this article